Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients

BACKGROUND: Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation beyond initial progression among recurrent glioblastoma patients as it is a comm...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Reardon, D A, Herndon, J E, Peters, K B, Desjardins, A, Coan, A, Lou, E, Sumrall, A L, Turner, S, Lipp, E S, Sathornsumetee, S, Rich, J N, Sampson, J H, Friedman, A H, Boulton, S T, Bigner, D D, Friedman, H S, Vredenburgh, J J
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2012
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3493761/
https://ncbi.nlm.nih.gov/pubmed/23037712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.415
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi